Adaptin Bio, Inc. APTN

Annual Quarterly

No annual revenue total was found in Adaptin Bio, Inc.'s SEC filings.

Adaptin Bio, Inc. (APTN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).

Revenue
—
Net income (TTM)
$-5.40M
-32.0% vs year-ago TTM
Operating cash flow (TTM)
$-2.52M
+31.1% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.63
+20.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
8.90M
+1.3% vs prior year
Net cash
—
Operating margin
—

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
APTN (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Charlotte, NC
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1938571
Former names
Unite Acquisition 1 Corp. (until Feb 13, 2025)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
Operating income
-$5.4M
-$2.6M
—
Net income
-$5.2M
-$3.1M
-$85,593
Diluted EPS
-$0.66
-$0.96
-$0.02
Operating cash flow
-$4.8M
-$649,283
-$81,035
Total assets
$619,159
$239,415
$380
Total liabilities
$2.1M
$4.3M
$113,277
Stockholders' equity
-$1.5M
-$4.1M
-$977,559
Cash and investments
$459,174
—
$380

Recent SEC filings

Form Description Filed Period
8-K Current report
Other events
 Aug 25, 2026 Aug 20, 2026
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
10-K/A Amended annual report Jun 12, 2026 Dec 31, 2025
10-Q Quarterly report May 15, 2026 Mar 31, 2026
8-K Current report
Other events
 Apr 6, 2026 Apr 6, 2026
10-K Annual report Apr 1, 2026 Dec 31, 2025

All 75 Adaptin Bio, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.